Sophie von Dyrander

“My decision to join Catenion? Here I found what I was looking for – high level strategy work, international clients and the team spirit of a smaller firm.”

Webpage Slider Sarah Oelsner

“From bench to bedside and beyond: Translating inspiring science into innovative business strategies is a fascinating journey”

Matthias Krings

“Change-Management is a team effort – let’s get started”

Dr. Matthias Krings Senior Partner
Christian Elze

“China’s policy makers are making a concerted long-term effort to build a competitive biomedical innovation system – but R&D-based value creation
is only just beginning.”

Christian Elze Senior Partner
Webpage Slider Pascal Joly

“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.“

Pascal Joly Analyst
Graham Scholefield

“Sitting at the boundary between science and business is an incredibly rewarding experience”

Markus Thunecke

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner
COG 150326_Catenion_0233

“I help R&D teams deliver on the promise of gene therapy”

Webpage Slider Anela Vukoja

„How can patients and the legislature steer the biopharmaceutical industry towards sustainable innovation?“

Dr. Anela Vukoja Associate
Webpage Slider Arno Heuermann

“Translating new technologies into viable business ideas”

Arno Heuermann COO, Partner, Managing Director
Webpage Slider Jonathan Vonnemann

“Uncovering the real value of technologies for our clients by seeing through the smoke and mirrors of the industry is just one of the fascinating aspects of working at Catenion”

DLI 150326_Catenion_8264

“We help our clients to achieve best practise in managing R&D performance”

Spotlight

Financier – M&A in biopharma – why bigger is not better

Numerous studies by academics and consultants demonstrate that M&A, on average, destroys value. A recent study performed on the Russe II 3000 index from 2001 to 2013 shows that most M&A is dilutive to earnings growth over an extended period post-merger. …
Download this article

Focus on 2017

Medicine Maker, January 2017 - It seems likely that 2016 will go down as one of the most eventful years in modern history, but what did the pharma industry make of it? Here, we quiz a number of past contributors to The Medicine Maker for their opinions on 2016 – and ask them what priorities [...]
Download this article

Meet Us

March 6 - 9, 2018

Pharma PPM Toolbox, workshop and conference, London

more
Jan 20, 2018

The New York Academy of Sciences, RiskyBusiness, NewYork

Nov. 13-15, 2017

PRECISION MEDICINE, Berlin

more
Nov. 8th, 2017

Tokyo University – Cultural Challenges in Translational Research

more
Nov. 8, 2017

University of Cambridge, Career Event, Cambridge, UK

more
Nov. 6-8, 2017

Bio-Europe, Berlin

more
Nov. 5, 2017

Bio-Europe Catenion Welcome Reception, PanAm Lounge Berlin

more
Oct. 28, 2017

University of Oxford, Career Fair, Oxford, UK

more
Sep. 25, 2017

Cell & Gene Terapy CEO, Boston

more
Sep. 20-21, 2017

Immuno-oncology Frontiers, Berlin

more